D-Chiro-Inositol
CAS 643-12-9
HPLC Assay99.0–102.0% HPLC
D-chiro-inositol powder for metabolic-nutrition formulations, distinct from myo-inositol
D-Chiro-Inositol Powder (CAS 643-12-9), specification 99.0–102.0% HPLC. D-Chiro-Inositol evaluated by HPLC assay and optical rotation, with stereochemistry distinct from myo-inositol. Batch COA and evaluation samples are available. MOQ: 1 kg. healthy-aging ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | D-chiro-inositol powder for metabolic-nutrition formulations, distinct from myo-inositol |
| Application Scenarios | metabolic research · nutrition formulation screening · stereochemical qualification |
| CAS Number | 643-12-9 |
| HPLC Assay | 99.0–102.0% HPLC |
| Molecular Formula | C6H12O6 |
| Molecular Weight | 180.16 g/mol |
| Appearance | White to off-white crystalline powder |
| Solubility | Soluble in water; confirm concentration and pH |
| Storage | Sealed, cool, dry and protected from light |
| Shelf Life | 2 years |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
D-chiro-inositol is a stereochemically defined inositol form. The current COA reports HPLC assay and optical rotation separately, so both identity and stereochemical control should be reviewed during qualification. They are different stereoisomers. Specify D-chiro-inositol CAS 643-12-9 and verify identity and optical rotation alongside assay; a generic inositol name or molecular formula is not sufficient. Product image: AI-generated ingredient illustration; actual batch appearance is subject to the sample and COA.
D-Chiro-Inositol Bulk Supply
PathGene supplies D-Chiro-Inositol, CAS 643-12-9, with specification 99.0–102.0% HPLC.
Ingredient Identity
D-Chiro-Inositol evaluated by HPLC assay and optical rotation, with stereochemistry distinct from myo-inositol.
Batch Quality Documentation
Batch COA supports the quality evaluation of D-Chiro-Inositol and the agreed purchasing specification.
Evaluation Samples
Request D-Chiro-Inositol samples for incoming-quality evaluation and project trials.
Supply and Packaging
MOQ: 1 kg. Packaging options: 1 g, 100 g, 1 kg, 25 kg.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PGDCI-260409
Test date
2026-04-10
Specification
Q/PG-INHOUSE
Pack size
25 kg/drum
Storage
Sealed, cool, dry and protected from light
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Assay (HPLC) | 99.0–102.0% | 99.8% |
| Optical rotation | +63.0° to +67.0° (c=1.0, H2O) | +63.3° |
| Loss on drying | ≤2.0% | 0.05% |
| Any unknown impurity | ≤0.1% | <0.1 |
| Heavy metals | ≤10 ppm | <10 |
View an available COA in the quality documents section. Check the document for its product form and batch; request a signed COA for your purchasing or shipment batch separately.
Hard capsules
Powders
Softgels
Tablets
Sublingual tablets
Oral dissolving films
Verify D-chiro and myo-inositol identity and assay separately; a study ratio is not a universal formulation ratio.
99.8%
Assay (HPLC)
<0.1
Any unknown impurity
PGDCI-260409 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Study combinations, individual-ingredient mechanisms and product precedents are distinguished; expand each entry for scope and pilot-development checks.
D-chiro-inositol is commonly studied alongside myo-inositol in defined-ratio formulations. For formulation R&D, compare several literature-informed ratios as separate prototypes and document assay basis, isomer identity, blend uniformity, dissolution and stability; do not infer one universal ratio from studies in different populations and settings.
Expand research and formulation notes +Collapse research and formulation notes −Development rationale: D-chiro-inositol is commonly studied alongside myo-inositol in defined-ratio formulations. For formulation R&D, compare several literature-informed ratios as separate prototypes and document assay basis, isomer identity, blend uniformity, dissolution and stability; do not infer one universal ratio from studies in different populations and settings.
Evidence scope: Randomized studies have examined MI+DCI formulations in specific PCOS populations, but used different ratios and designs. They are not a universal dose or medical recommendation, and do not validate this DCI raw material or a new finished formula; check target-market rules before making reproductive-health claims.
Pilot checks: Retain individual-ingredient, blend and carrier controls; check uniformity and post-process assays before packaged samples, documenting study formulations separately from new candidates.
2016 · A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. ↗Literature-Supported Research Directions
The IUPHAR/BPS ligand entry identifies D-chiro-inositol (DCI) and notes that PubChem CID 892 represents a non-chiral inositol structure. Use stereochemical identity data and the batch COA to qualify the supplied material.
Citation: IUPHAR/BPS Guide to Pharmacology, ligand 4645View source
A 1999 randomized placebo-controlled trial studied D-chiro-inositol in 44 women with PCOS over six to eight weeks and measured insulin responses, reproductive hormones and ovulation. The results concern a defined clinical population and study protocol; this page presents them as literature context, not a product treatment claim.
Citation: Nestler et al. New England Journal of Medicine. 1999;340:1314–1320.View source
Some clinical studies have evaluated myo-inositol together with D-chiro-inositol at specified ratios. Such combination trials can inform formulation research, but cannot isolate the contribution of DCI alone or establish equivalence to a standalone DCI ingredient.
Citation: Kachhawa et al. International Journal of Gynecology & Obstetrics. 2022;158(2):278–284.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
1 kg
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
The stated purity and batch result are shown separately. Confirm the method, dry-basis calculation and salt or hydrate form against the current COA.
Formulation work should confirm concentration, pH, light, moisture and hold-time controls for D-Chiro-Inositol; suitability depends on the final format and market requirements.
The raw-material MOQ for D-chiro-inositol powder is 1 kg, with pack options of 1 g, 100 g, 1 kg, 25 kg. DCI and myo-inositol are distinct materials and should be identified separately in orders.
They are different stereoisomers. Specify D-chiro-inositol CAS 643-12-9 and verify identity and optical rotation alongside assay; a generic inositol name or molecular formula is not sufficient.
D-Chiro-Inositol powder, CAS 643-12-9, has an HPLC assay specification of 99.0–102.0%. Qualification should review identity, assay and optical-rotation documentation to distinguish DCI from other inositol isomers.
For D-chiro-inositol and myo-inositol blends, verify each ingredient’s identity and assay, calculate the ratio on the agreed mass or molar basis, and assess blend uniformity and stability in the intended format. Interpret study or finished-product ratios in their specific populations and protocols, rather than as universal formulation ratios.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Related Products
Spermidine Trihydrochloride Powder
Pyrroloquinoline Quinone Disodium Salt Powder
Interested in D-Chiro-Inositol?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
